Tags

Type your tag names separated by a space and hit enter

Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction.
Arterioscler Thromb Vasc Biol 2002; 22(7):1155-61AT

Abstract

OBJECTIVE

We have examined the association between the incidence of coronary heart disease (CHD) and plasma high density lipoprotein (HDL) cholesterol, apolipoprotein A-I (apoA-I), and 2 HDL fractions, lipoprotein A-I and lipoprotein A-I:A-II.

METHODS AND RESULTS

These parameters were measured in subjects recruited in France and in Northern Ireland in the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study, a prospective cohort study. Among the subjects free of CHD on entry, 176 in France and 113 in Northern Ireland suffered an ischemic attack (CHD patients) during the 5-year follow-up, whereas 6612 French and 2172 Northern Irish men showed no CHD symptoms (CHD-free subjects). All 4 HDL parameter levels were lower in CHD patients than in CHD-free subjects. After the cohort was divided into quintiles based on the distribution of HDL parameter levels, a significant (P<0.0001) linear increase in relative risk was observed for each HDL parameter level. However, regression logistic analyses showed that apoA-I was the strongest predictor (more powerful than HDL cholesterol) and that lipoprotein A-I and lipoprotein A-I:A-II did not supplement apoA-I in predicting CHD.

CONCLUSIONS

Among the parameters related to HDL, apoA-I appears to be the strongest independent risk factor.

Authors+Show Affiliations

Department of Atherosclerosis, INSERM UR545, Institut Pasteur de Lille, and University Lille II, Lille, France. Gerald.Luc@pasteur-lille.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Validation Studies

Language

eng

PubMed ID

12117731

Citation

Luc, Gérald, et al. "Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 7, 2002, pp. 1155-61.
Luc G, Bard JM, Ferrières J, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2002;22(7):1155-61.
Luc, G., Bard, J. M., Ferrières, J., Evans, A., Amouyel, P., Arveiler, D., ... Ducimetière, P. (2002). Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 22(7), pp. 1155-61.
Luc G, et al. Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1155-61. PubMed PMID: 12117731.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. AU - Luc,Gérald, AU - Bard,Jean-Marie, AU - Ferrières,Jean, AU - Evans,Alun, AU - Amouyel,Philippe, AU - Arveiler,Dominique, AU - Fruchart,Jean-Charles, AU - Ducimetière,Pierre, PY - 2002/7/16/pubmed PY - 2002/8/3/medline PY - 2002/7/16/entrez SP - 1155 EP - 61 JF - Arteriosclerosis, thrombosis, and vascular biology JO - Arterioscler. Thromb. Vasc. Biol. VL - 22 IS - 7 N2 - OBJECTIVE: We have examined the association between the incidence of coronary heart disease (CHD) and plasma high density lipoprotein (HDL) cholesterol, apolipoprotein A-I (apoA-I), and 2 HDL fractions, lipoprotein A-I and lipoprotein A-I:A-II. METHODS AND RESULTS: These parameters were measured in subjects recruited in France and in Northern Ireland in the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study, a prospective cohort study. Among the subjects free of CHD on entry, 176 in France and 113 in Northern Ireland suffered an ischemic attack (CHD patients) during the 5-year follow-up, whereas 6612 French and 2172 Northern Irish men showed no CHD symptoms (CHD-free subjects). All 4 HDL parameter levels were lower in CHD patients than in CHD-free subjects. After the cohort was divided into quintiles based on the distribution of HDL parameter levels, a significant (P<0.0001) linear increase in relative risk was observed for each HDL parameter level. However, regression logistic analyses showed that apoA-I was the strongest predictor (more powerful than HDL cholesterol) and that lipoprotein A-I and lipoprotein A-I:A-II did not supplement apoA-I in predicting CHD. CONCLUSIONS: Among the parameters related to HDL, apoA-I appears to be the strongest independent risk factor. SN - 1524-4636 UR - https://www.unboundmedicine.com/medline/citation/12117731/Value_of_HDL_cholesterol_apolipoprotein_A_I_lipoprotein_A_I_and_lipoprotein_A_I/A_II_in_prediction_of_coronary_heart_disease:_the_PRIME_Study__Prospective_Epidemiological_Study_of_Myocardial_Infarction_ L2 - http://www.ahajournals.org/doi/full/10.1161/01.atv.0000022850.59845.e0?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -